ProCE Banner Series

16th Annual CCO/IMF Hematology Symposium: Experts Discuss the Current State and Future Perspectives in Myeloma Care

Register now to join us for one of 2 CME-certified virtual symposia following the 65th ASH Annual Meeting, where leading myeloma experts will provide invaluable insights into the ever-evolving treatment landscape for multiple myeloma, ensuring healthcare professionals stay at the forefront of cutting-edge therapies and innovations. Don’t miss this opportunity to gain in-depth knowledge and CME credits while connecting with thought leaders in the field.

To Register: Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  AMA
Who Should Attend

This program is intended for physicians and other healthcare professionals who care for patients with multiple myeloma.

All Events

16th Annual CCO/IMF Hematology Symposium: Experts Discuss the Current State and Future Perspectives in Myeloma Care

Past Events

December

18

2023

12:30 PM - 2:00 PM Eastern Time (ET)

Virtual

January

18

2024

12:30 PM - 3:00 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

ProCE Banner Faculty
Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Lead, Cancer Immunology and Immunotherapy Program
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

ProCE Banner Faculty
Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital of Nantes
Nantes, France

ProCE Banner Faculty
S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps–Edward C. Rosenow, III, MD
Professor of Medicine
Associate Editor, Mayo Clinic Proceedings
Mayo Clinic
Rochester, Minnesota

ProCE Banner Faculty
Jesús F. San-Miguel

Professor of Medicine
Senior Consultant
Cancer Center Clínica Universidad de Navarra
Pamplona, Spain

Topics

Welcome and Introduction by Moderator Brian G.M. Durie, MD

Real-world Cases and Panel Discussions

  • When Do You Consider Therapy for Patients With Smoldering MM?
  • What Induction Therapy Is Optimal for Patients With Newly Diagnosed MM?
  • What Should the Ideal Duration of Therapy Be for First-line MM?
  • What Is the Optimal Management of R/R MM, Including Current Treatment Strategies for Sequencing Available Agents?
  • How Should You Incorporate Newest Updates on  Novel Approaches to Immunotherapy for R/R MM?

Introduction to the 2024 MM Care Algorithm

Audience Question and Answer Session

Closing Remarks

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, confidence, and competence in applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma. 

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Initiate timely systemic treatment for appropriate patients based on risk assessment and the latest multiple myeloma diagnostic and staging criteria
  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data as well as risk assessment, comorbidities, and patient age/fitness and preferences
  • Select optimal therapies for patients with heavily pretreated relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as response to and tolerance of previous therapies
  • Appraise the efficacy and safety evidence of novel therapeutics and emerging combination regimens for patients with multiple myeloma
  • Identify patients with relapsed/refractory multiple myeloma who would be eligible for enrollment on key ongoing clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC in partnership with the International Myeloma Foundation.

Supported by educational grants from Karyopharm Therapeutics, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.